Audi Said H, Merker Marilyn P, Krenz Gary S, Ahuja Taniya, Roerig David L, Bongard Robert D
Research Service 151, Zablocki VAMC, 5000 W. National Avenue, Milwaukee, WI 53295, USA.
J Appl Physiol (1985). 2008 Oct;105(4):1114-26. doi: 10.1152/japplphysiol.00177.2008. Epub 2008 Aug 14.
The objective was to evaluate the pulmonary disposition of the ubiquinone homolog coenzyme Q(1) (CoQ(1)) on passage through lungs of normoxic (exposed to room air) and hyperoxic (exposed to 85% O(2) for 48 h) rats. CoQ(1) or its hydroquinone (CoQ(1)H(2)) was infused into the arterial inflow of isolated, perfused lungs, and the venous efflux rates of CoQ(1)H(2) and CoQ(1) were measured. CoQ(1)H(2) appeared in the venous effluent when CoQ(1) was infused, and CoQ(1) appeared when CoQ(1)H(2) was infused. In normoxic lungs, CoQ(1)H(2) efflux rates when CoQ(1) was infused decreased by 58 and 33% in the presence of rotenone (mitochondrial complex I inhibitor) and dicumarol [NAD(P)H-quinone oxidoreductase 1 (NQO1) inhibitor], respectively. Inhibitor studies also revealed that lung CoQ(1)H(2) oxidation was via mitochondrial complex III. In hyperoxic lungs, CoQ(1)H(2) efflux rates when CoQ(1) was infused decreased by 23% compared with normoxic lungs. Based on inhibitor effects and a kinetic model, the effect of hyperoxia could be attributed predominantly to 47% decrease in the capacity of complex I-mediated CoQ(1) reduction, with no change in the other redox processes. Complex I activity in lung homogenates was also lower for hyperoxic than for normoxic lungs. These studies reveal that lung complexes I and III and NQO1 play a dominant role in determining the vascular concentration and redox status of CoQ(1) during passage through the pulmonary circulation, and that exposure to hyperoxia decreases the overall capacity of the lung to reduce CoQ(1) to CoQ(1)H(2) due to a depression in complex I activity.
目的是评估泛醌同系物辅酶Q(1)(CoQ(1))在通过常氧(暴露于室内空气)和高氧(暴露于85% O₂ 48小时)大鼠肺部时的肺内处置情况。将CoQ(1)或其对苯二酚(CoQ(1)H₂)注入离体灌注肺的动脉流入端,并测量CoQ(1)H₂和CoQ(1)的静脉流出率。注入CoQ(1)时,CoQ(1)H₂出现在静脉流出液中;注入CoQ(1)H₂时,CoQ(1)出现。在常氧肺中,注入CoQ(1)时,CoQ(1)H₂的流出率在存在鱼藤酮(线粒体复合物I抑制剂)和双香豆素[NAD(P)H-醌氧化还原酶1(NQO1)抑制剂]时分别降低了58%和33%。抑制剂研究还表明,肺CoQ(1)H₂氧化是通过线粒体复合物III进行的。在高氧肺中,注入CoQ(1)时,CoQ(1)H₂的流出率与常氧肺相比降低了23%。基于抑制剂作用和动力学模型,高氧的影响主要可归因于复合物I介导的CoQ(1)还原能力降低47%,而其他氧化还原过程无变化。高氧肺匀浆中的复合物I活性也低于常氧肺。这些研究表明,肺复合物I和III以及NQO1在决定CoQ(1)在肺循环中通过时的血管浓度和氧化还原状态方面起主导作用,并且暴露于高氧会由于复合物I活性降低而降低肺将CoQ(1)还原为CoQ(1)H₂的总体能力。